Biotechnology

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

February 20, 2025 9:00 AM

POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health solutions. Holiby is scaling its commercial strategy through direct-to-consumer e-commerce, white-label and private-label partnerships,...

Read more

Mr. Chain Introduces EarthMade(TM) Line of Plastic Chain Featuring Verde Bioresins' Biodegradable Polyethylene

February 20, 2025 8:00 AM

Verde Bioresins, a pioneer in sustainable polymer technology, announces its partnership with Mr. Chain, a leading U.S. manufacturer of plastic barrier chain and stanchions, in the launch of Mr. Chain's revolutionary EarthMade™ line of plastic chain, made with Verde biobased and biodegradable line of PolyEarthylene™ resins. This industry-first innovation represents a significant milestone in sustainable materials, offering a more eco-friendly...

Read more

Jord BioScience Secures Series B Funding to Revolutionize Microbial Solutions for Agriculture

February 19, 2025 9:30 AM

Jord BioScience, a leading science and analytics company providing customizable microbial solutions for agriculture, announced the closing of its Series B round. This funding round will accelerate Jord BioScience's development and commercialization of innovative microbial technologies to deliver next-generation crop inputs. Lead investor Silver Blue LLC, a Maryland-based firm focusing on agrifoodtech, was joined by Discovery Capital Funding, a...

Read more

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, Robert Berman, Chief Executive Officer of enVVeno, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the...

Read more

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025 9:00 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, James Bianco, M.D., President and Chief Executive Officer of TuHURA, presented the top five reasons of why he believes the investment community and...

Read more

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

February 19, 2025 8:45 AM

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025. IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...

Read more

Doron Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MOTYS for Treatment of Symptoms Associated With Osteoarthritis

February 19, 2025 8:00 AM

Doron Therapeutics, a clinical-stage biotechnology company focusing on degenerative musculoskeletal conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MOTYS™, its lead placental tissue-derived biologic in clinical development for the treatment of symptoms associated with knee osteoarthritis (OA). In addition to RMAT, MOTYS was also granted Fast...

Read more

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

February 18, 2025 9:25 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces the pricing of a public offering of approximately 40,000,000 shares of the Company's common stock ("Common Stock"), par value $0.0001 per share (or pre-funded warrants in lieu thereof), with each share of Common Stock (or pre-funded...

Read more

IGC Pharma Reports Third Quarter Fiscal 2025 Results

February 18, 2025 8:30 AM

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr. Ram Mukunda, CEO. "We are also planning to explore IGC-AD1 as an Alzheimer's disease-modifying therapy, aimed at reducing...

Read more

Foxx Life Sciences Hosts Successful Open House Event in Hyderabad, India

February 17, 2025 5:00 AM

Foxx Life Sciences is delighted to announce the successful completion of its Open House event, held at the company's facility in Hyderabad, India. The event was well attended by industry leaders, partners, and community members, marking a significant milestone in Foxx Life Sciences ongoing commitment to innovation and excellence in the life sciences sector. Foxx celebrated 5 years of Bioprocess manufacturing in India and 2 new manufacturing...

Read more

Alligator Bioscience Announces Final Outcome in Rights Issue

February 14, 2025 11:15 AM

The Board of Directors of Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience" or the "Company"), today announces the final outcome of the rights issue of units that was announced on 2 December 2024 (the "Rights Issue"). The final outcome shows that 1,429,045,434 units, corresponding to approximately 50.8 percent of the Rights Issue, have been subscribed for by exercise of unit rights. In addition, 100,971,492 units have been subscribed...

Read more

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025

February 14, 2025 8:00 AM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on...

Read more

Aspira Women's Health Submits Request for Withdrawal of Form S-1 Registration Statement

February 13, 2025 10:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333-284182), as amended, originally filed on January 8, 2025 (the "Registration Statement"),...

Read more

Alligator Bioscience Announces Preliminary Outcome in Rights Issue

February 13, 2025 6:40 AM

Alligator Bioscience (STO:ATORX) The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company"), today announces the preliminary outcome of the rights issue of units that was announced on 2 December 2024 (the "Rights Issue"). The preliminary outcome indicates that the Rights Issue has been subscribed to approximately 54.4 percent with and without exercise of unit rights, of which approximately 50.8 percent were...

Read more

ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula

February 12, 2025 4:15 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula. The SmartFlow Cannula was previously cleared under the Medical Device Directive 93/42/EEC (MDD) and has now successfully achieved the more rigorous EU MDR certification well...

Read more

Biolog Purchases Anaerobe Systems, Its Third Acquisition, Becoming the Knowledge Leader in Microbiology Research and Clinical Sample Prep

February 12, 2025 6:00 AM

Biolog, Inc., a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, today announced the acquisition of Anaerobe Systems, Inc. headquartered in Morgan Hill, California. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation Technologies....

Read more

Aspira Women's Health Announces Appointment of Ellen Beausang to the Board of Directors

February 11, 2025 8:30 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Ellen Beausang to the Board of Directors, effective February 10, 2025. "We are pleased to welcome Ellen Beausang to the Board of Directors," said Michael Buhle, Chief Executive Officer of Aspira Women's Health. "Ellen brings an...

Read more

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

February 11, 2025 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion into the rapidly growing $75 billion wellness industry establishes a new revenue stream while IGC Pharma continues advancing its pharmaceutical pipeline focused on treatments for Alzheimer's disease and metabolic...

Read more

ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community

February 11, 2025 7:00 AM

ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine and the development and sales of biologic products used in topical aesthetic applications, today provided a business update to stockholders and the investment community. The Opportunity As of the end...

Read more

Next Gen Diagnostics Announces That the University of Pittsburgh Has Joined the NGD Consortium

February 10, 2025 12:00 PM

Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based determination of bacterial antibiotic susceptibility, today announces that the University of Pittsburgh (Pitt) has joined the NGD Consortium, a part of NGD's effort (1) to develop a sequence-based diagnostic model to predict susceptibility to cefiderocol, an antibiotic developed by Shionogi & Co., Ltd. (Shionogi)....

Read more